Finerenone, sold by Bayer under the brand name Kerendia, is now approved in the United States for the treatment of HFmrEF and HFpEF. The drug has already been used for years to treat patients with chronic kidney disease and type 2 diabetes.
Edwards Lifesciences has recalled more than 61,000 medical devices due to the risk of a small piece of wire becoming exposed. No patient injuries have been reported at this time.
The Symplicity Spyral RDN system. Graphic courtesy of Medtronic.
This proposal, if finalized, would dramatically increase patient access to renal denervation. Both Recor Medical and Medtronic have shared their excitement over the news.
Researchers have been spending more and more time evaluating the Myval TAVR valve from Indian medtech company Meril Life Sciences. The balloon-expandable device is available in some parts of the world, but not the United States.
CMS has finalized a new national coverage determination for T-TEER, sometimes known as transcatheter tricuspid valve repair. Abbott's TriClip is the only device approved by the FDA for T-TEER, but other treatment options are under development.
The CorWave technology is unlike other left ventricular assist devices, working in harmony with the patient's heartbeat and making adjustments as needed.
![Ultromics EchoGo Amyloidosis artificial intelligence. A first of its kind AI model developed by Mayo Clinic and Ultromics Ltd., was found to be highly accurate in screening for cardiac amyloidosis in a large 2,612 patient clinical trial. The findings were published in the European Heart Journal.[1] Mayo Clinic, investigators at the University of Chicago Medicine and collaborators around the world at other sites, validated and tested the model on a large and multi-ethnic population.](/sites/default/files/styles/top_stories/public/2024-11/screenshot_2024-11-21_at_8.03.58_am.png.webp?itok=t6ancPrf)
